Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ablynx Licenses anti-RANKL Nanobody to Eddingpharm | Contract Pharma

What are you searching for?

Sign in
Breaking News

Ablynx Licenses anti-RANKL Nanobody to Eddingpharm

Will receive €2 million upfront plus milestones and royalties

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ablynx has granted an exclusive license to its anti-RANKL Nanobody, ALX-0141, to Eddingpharm, a Chinese specialty pharmaceutical company. Eddingpharm will develop and commercialize ALX-0141 in China, Hong Kong and Macao Special Administrative Regions, and Taiwan, for all indications, including osteoporosis and bone metastases.
 
Eddingpharm will be responsible for clinical development, registration and commercialization of anti-RANKL Nanobody therapeutics. Ablynx will have access to the data generated to support potential licensing discussions in other geographic regions. Ablynx will receive €2 million upfront and is entitled to receive commercial milestones plus royalties on sales.
 
ALX-0141 is a bivalent bi-specific therapeutic molecule composed of two Nanobodies targeting the Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL). A Phase I study showed that a single administration of ALX-0141 has a strong and long-lasting inhibitory effect on bone resorption biomarkers and was well tolerated with no serious adverse events.
 
Dr. Edwin Moses, chairman and chief executive officer of Ablynx said, “Eddingpharm is well-positioned to further develop and commercialize ALX-0141 in Greater China, which represents a rapidly growing area for bone related disorders. Our Nanobody has strong potential in this market, with very good efficacy, as measured by biomarkers, and a clean safety profile, and we look forward to collaborating with Eddingpharm and supporting them to move the program further in development and beyond.”
 
Ni Xin, founder, chairman and chief executive officer of Eddingpharm said,”We are very pleased that Ablynx has entrusted Eddingpharm to develop and commercialize its anti-RANKL Nanobody in Greater China. Together with Ablynx, we are committed to bringing this innovative medicine to millions of patients in the region. This partnership represents a key milestone towards our goal of establishing Eddingpharm as the partner of choice in China for biotechnology companies around the world.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics